Americans seeking to lose weight now have a new option – taking Wegovy as a daily pill, rather than a weekly injection.

Does the new Wegovy pill work as well as Wegovy injections for weight loss? How else does it compare? Learn what the experts ...

With just a few months to go before Eli Lilly expects to launch its own oral GLP-1 obesity drug, Novo Nordisk is making the ...

By Amina Niasse NEW YORK, Jan 28 (Reuters) - Telehealth company Ro has had an influx of new customers seeking the newly ...

FDA has approved Novo Nordisk's once daily oral Wegovy pill for obesity and cardiovascular risk reduction, and the product has now launched in the U.S. The oral format offers an alternative to ...

While injectable medications have dominated the weight loss space for years, most people aren’t exactly pumped to stick a needle in their stomach on a weekly basis. Now, a potential game-changing ...

A new Wegovy pill is now available nationwide, giving adults a daily tablet option instead of weekly shots for weight loss ...

Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]) and ...

A NEW jab set to rival the likes of Mounjaro and Wegovy helped people lose up to 22 per cent of their body weight in less ...

Novo Nordisk entered 2026 with fresh momentum after the U.S. launch of its oral Wegovy pill. Is the stock a buy now?

Novo Nordisk (NVO) stock is in focus as the Wegovy pill tops 3,071 U.S. scripts in the first 4 days of its launch. Read more ...

Despite ushering in the current GLP-1 era, Novo Nordisk has fallen behind its chief rival Eli Lilly, which has exceeded the Danish pharma in terms of sales.